BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Motesanib: Phase III data

Top-line data from the double-blind Phase III MONET1 trial in 1,090 patients with advanced non-squamous NSCLC showed that once-daily 125 mg oral motesanib plus carboplatin and paclitaxel as first-line therapy missed the primary endpoint of significantly improving OS vs. placebo plus carboplatin and paclitaxel (p=0.14). Adverse events included hypertension, gastrointestinal and gallbladder events, fatigue and hematological events.


Read the full 271 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >